|Bid||5.87 x 900|
|Ask||5.89 x 600|
|Day's Range||5.76 - 5.99|
|52 Week Range||4.97 - 10.73|
|PE Ratio (TTM)||-7.47|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
LEAWOOD, Kan., May 16, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics ...
Q1 2017 Aratana Therapeutics Inc Earnings Call
Aratana Therapeutics is on track to hit a big sales milestone for its planned blockbuster drug and is making moves to stockpile more of it. The Leawood-based animal health company is seeing strong demand for its canine osteoarthritis drug, Galliprant, licensed through Eli Lilly and Co.’s (LLY) animal health subsidiary. “We’re very pleased with where Galliprant is.